For Investors

We work with investors who share a long-term perspective on healthcare value and commercial performance.

Triquetra Medicines operates as a strategic development and holding company. Investment opportunities are offered through dedicated execution vehicles—autonomous subsidiaries built around a specific product and its associated expansion potential.

We do not seek capital for speculative research. We focus on opportunities supported by substantial scientific and clinical validation, where value can be realized through structured development and implementation.

Our model is built on the premise that durable healthcare value and durable commercial value follow the same logic.

Opportunities are designed for broad adoption, sustained utilization, and long-term positioning. Value is not extracted early. It is built over time.

Our model allows capital to be deployed where conventional programs can no longer justify it.

This differs from conventional pharmaceutical investment models. Capital structures and exit pathways are therefore defined case by case.

Depending on the opportunity, this may include licensing transactions, royalty structures, strategic sales, redemption mechanisms, secondary liquidity pathways, or other tailored approaches.

We value engaged, capable partners. Capital alone is not sufficient.

We seek investors who can contribute to development, execution, governance, or healthcare impact—and who are aligned with a long-term approach to value creation.